a. Department of Urological Surgery, b. Department of Physical Examination and Health Care, the Affiliated Luohu Hospital of Anhui University of Science and Technology, Shenzhen 518000, China
Abstract：In the current clinical medication, there is no method to confirm the sensitivity of patients with different genotypes to corresponding anticancer-drugs and also lack of response to side effects and drug resistance. In recent years, the development of high-throughput technology has made it possible to screen chemotherapeutic drugs on a large scale in cancer cell lines, and generated a large number of omics-data. Currently, based on these data, many predictive models of anticancer-drugs have been established, which will be helpful to predict and optimize the drug targets for cancer patients. This paper reviews the research progress of anticancer-drug prediction models.
MCGRANAHAN N, SWANTON C. Clonal heterogeneity and tumor evolution: past, present, and the future[J]. Cell, 2017, 168(4): 613-628.
[2]
ZIEGELSTEIN R C. Personomics[J]. JAMA Inter Med, 2015, 175(6): 888-889.
[3]
WU M L, ZHU Z Y, WANG J.Prediction of serum valproic acid concentration of epiletic children with back propagation neural network model[J]. Chin Pharm J (中国药学杂志),2012, 47(10):766-770.
[4]
GHANDI M, HUANG F W, JAN-VALBUENA J, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia[J]. Nature, 2019, 569(7757): 503-508.
[5]
ANSARI A A, PARK I, KIM I, et al. Genomics of drug sensitivity in bladder cancer: an integrated resource for pharmacogenomic analysis in bladder cancer[J]. BMC Med Genomics, 2018, 11(1): 88.
[6]
FANG Y, XU P, YANG J, et al. A quantile regression forest based method to predict drug response and assess prediction reliability[J]. PLoS One, 2018, 13(10): e0205155.
[7]
FERNNDEZ-DELGADO M, SIRSAT M S, CERNADAS E, et al. An extensive experimental survey of regression methods[J]. Neural Netw, 2019, 111: 11-34.
[8]
DONG Z, ZHANG N, LI C, et al. Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection[J]. BMC Cancer, 2015,15:489.
[9]
ZHANG F, WANG M, XI J, et al. A novel heterogeneous network-based method for drug response prediction in cancer cell lines[J]. Sci Rep, 2018, 8(1): 3355.
[10]
SEAL A, AHN Y Y, WILD D J. Optimizing drug-target interaction prediction based on random walk on heterogeneous networks[J]. J Cheminform, 2015, 7: 40.
[11]
YANG J, LI A, LI Y, et al. A novel approach for drug response prediction in cancer cell lines via network representation learning[J]. Bioinformatics, 2019, 35(9):1527-1535.
[12]
GOYAL P, FERRARA E. Graph embedding techniques, applications, and performance: a survey[J]. Knowledge-Based Systems, 2018, 151: 78-94.
[13]
JIAN T, MENG Q, WANG M, et al. LINE: Large-scale Information Network Embedding[C]. Proceedings of the 24th International Conference on World Wide Web, 2015: 1067-1077.
[14]
MENDEN M P, IORIO F, GARNETT M, et al. Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties[J]. PLoS One, 2013, 8(4): e61318.
[15]
LE D H, PHAM VHJJO M B. Drug response prediction by globally capturing dru and cell line information in a heterogeneous network[J]. J Mol Biol, 2018, 430(18 Pt A):2993-3004.
[16]
GUO T, LUNA A, RAJAPAKSE V N, et al. Quantitative proteome landscape of the NCI-60 cancer cell lines[J]. iScience, 2019, 21: 664-680.
[17]
POLYMENIS M. Proteins associated with the doubling time of the NCI-60 cancer cell lines[J]. Cell Div, 2017,12(1): 6.
[18]
RAJAPAKSE V N, LUNA A, YAMADE M, et al. CellMinerCDB for integrative cross-database genomics and pharmacogenomics analyses of cancer cell lines[J]. iScience, 2018, 10: 247-264.
[19]
LEE J K, HAVALESHKO D M, Hyungjun C, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery[J]. Proc Natl Acad Sci USA, 2007, 104(32): 13086-13091.
[20]
GUSTAFSON D L, FOWLES J S, BROWN K C, et al. Drug selection in the genomic age: application of the coexpression extrapolation principle for drug repositioning in cancer therapy[J]. Assay Drug Dev Technol, 2015, 13(10): 623-627.
[21]
SOUKUP M, CHO H J, LEE J K. Robust classification modeling on microarray data using misclassification penalized posterior[J]. Bioinformatics, 2005,21(suppl 1):i423-i430.
[22]
HAVALESHKO D M, CHO H, CONAWAY M, et al. Prediction of drug combination chemosensitivity in human bladder cancer[J]. Mol Cancer Ther, 2007, 6(2): 578-586.
[23]
HARDING M A, ARDEN K C, GILDEA J W, et al. Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling[J]. Cancer Res, 2002, 62(23): 6981-6989.
[24]
EARL J, RICO D, CARRILLO-DE-SANTA-PAU E, et al. The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies[J]. BMC Genomics, 2015, 16(1):1019.
[25]
RAY K K, BAYS H E, CATAPANO A L, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol[J]. N Engl J Med, 2019, 380(11): 1022-1032.
[26]
GOULD S, R JUNTTILA M, J D E SAUVAGE F. Translational value of mouse models in oncology drug development[J]. Nat Med, 2015, 21(5):431-439.
[27]
BAKER A E G, BAHLMANN L C, TAM R Y, et al. Benchmarking to the gold standard: hyaluronan-oxime hydrogels recapitulate xenograft models with in vitro breast cancer spheroid culture [J]. Adv Mater, 2019, 31(36):e1901166.
[28]
GAULTON A, HERSEY A, NOWOTKA M, et al. The ChEMBL database in 2017[J]. Nucleic Acids Res, 2017, 45(D1):D945-D954.
[29]
CARLOTA R P, DAVID T, SCHROEDER M P, et al. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities[J]. Cancer Cell, 2015, 27(3): 382-396.
[30]
IORIO F, KNIJNENBURG T, VIS D, et al. A landscape of pharmacogenomic interactions in cancer[J]. Cell, 2016, 166(3):740-754.
[31]
WAAL L D, LEWIS T A, REES M G, et al. Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics[J]. Nat Chem Biol, 2016, 12(2): 102-108.
[32]
JOHANNESSEN C M, CLEMONS P A, WAGNER B K. Integrating phenotypic small-molecule profiling and human genetics: the next phase in drug discovery[J]. Trends Genet, 2015, 31(1): 16-23.
2020, Vol. 55 
